Drug Trial Radar · NCT00001038
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
Last checked: Nov 19, 2026Latest source record: Mar 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Not stated
Primary completion
May 1996
Sponsor
- Sponsor type
- NIH
- Collaborators
- Glaxo Wellcome
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes \< 100 cells/mm3. To assess the impact of BW 256U87, high-dose oral acyclovir and low-dose oral acyclovir on survival. SECONDARY: To evaluate the effect of BW 256U87 on quality of life, the safety of the drug administered concurrently with standard antiretroviral agents and other essential therapies for the treatment and prevention of opportunistic diseases, and the efficacy of BW 256U87 in suppressing activation of other herpesviruses. To evaluate serologic and virologic risk factors for the development of CMV disease, including assessment of HIV activation, and the risk of developing drug-resistant CMV, HSV, and VZV. Gastrointestinal absorption of acyclovir is not high enough to prevent CMV disease in patients with advanced HIV disease, although there is evidence that high doses of the drug may extend survival. Valacyclovir, a prodrug that is rapidly converted to acyclovir after oral administration, has a higher absorption rate and may therefore provide inhibitory activity against CMV.
Conditions
- Cytomegalovirus Infections
- HIV Infections
Interventions
Valacyclovir hydrochlorideDrug
AcyclovirDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
35 sites in 10 countries. Site status is shown where the registry gives one.
Birmingham Veterans Administration Med Ctr
Birmingham, Alabama
Los Angeles County - USC Med Ctr
Los Angeles, California
CARE Ctr / UCLA Med Ctr
Los Angeles, California
Highland Gen Hosp / San Francisco Gen Hosp
Oakland, California
Univ of California / San Diego Treatment Ctr
San Diego, California
Kaiser Permanente Med Ctr
San Francisco, California
Univ of Colorado Health Sciences Ctr
Denver, Colorado
Yale Univ
New Haven, Connecticut
Northwestern Univ Med School
Chicago, Illinois
Indiana Univ Hosp
Indianapolis, Indiana
Johns Hopkins Hosp
Baltimore, Maryland
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts
Boston Med Ctr
Boston, Massachusetts
Washington Univ
St Louis, Missouri
Mount Sinai Med Ctr
New York, New York
North Central Bronx Hosp / Bronx Municipal Hosp
The Bronx, New York
Univ of North Carolina School of Medicine
Chapel Hill, North Carolina
Ohio State Univ Hosp Clinic
Columbus, Ohio
Girard Med Ctr
Philadelphia, Pennsylvania
Univ TX Galveston Med Branch
Galveston, Texas
Univ of Washington / Madison Clinic
Seattle, Washington
Saint Vincent's Hosp Med Centre
Sydney, Australia
Southern Alberta HIV Clinic / Foothills Hosp
Calgary, Alberta, Canada
Sunnybrook Health Science Ctr
Toronto, Ontario, Canada
Toronto Hosp
Toronto, Ontario, Canada
Montreal Chest Institute
Montreal, Quebec, Canada
Montreal Gen Hosp
Montreal, Quebec, Canada
Hvidovre Univ Hosp
Hvidore, Denmark
Services des Maladies Infectieuses
Paris, France
Universitatsklinikum Rudolf Virchow
Berlin, Germany
Universita Cattolica del Sacro Cuore
Rome, Italy
South Hosp
Stockholm, Sweden
Medizinische Universibatspoliklinik Infekbiologie
Bern, Switzerland
Royal Free Hosp
London, United Kingdom
Westminster Hosp
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.